Noveome Biotherapeutics has dosed the first patient in a phase 2 trial of ST266 for persistent corneal epithelial defects, according to a press release.
Subjects in the open-label, multicenter clinical trial will receive four topical doses per day of ST266, a cell-free platform biologic that contains hundreds of proteins, for the 28-day duration of the study. Complete healing of the defect, determined by fluorescein dye, is the primary endpoint of the trial.
“We believe that ST266 has the potential to provide an innovative treatment option as a novel cell-free platform biologic based on the results we have seen to date in both preclinical and clinical trials demonstrating a strong safety profile,” William J. Golden, founder, chairman and CEO of Noveome, said in the release. “In this trial, we will measure both the magnitude and speed of response, as well as the number of completely healed patients and the time to complete healing in the study eye of PED patients.”
Topline results are expected later this year.